Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-3373 with standard agents in colorectal cancer
NCT03428958Phase 2Completed
- Sponsor
- NuCana
- Start
- Oct 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of fosifloxuridine nafalbenamide in colorectal cancer (CRC), sponsored by NuCana. Started Oct 2018; status: completed.
02
Drugs
fosifloxuridine nafalbenamide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03428958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428958.